

## **CABS Posters**

For presentation during the Poster Reception 18:00-19:00 on Sunday 1 July and manned at the following times:

Odd numbers on Monday 2 July 13:20-14:00

Even numbers on Tuesday 3 July 13:20-14:00

P1

Abstract withdrawn

P2

Refilling of bony myeloma lytic lesions mediated by total therapy 4 treatment  
Maurizio Zangari (Little Rock, USA)

P3

Bone seeking MMP-2 inhibitors can prevent bone metastatic breast cancer  
Marilena Tauro (Tampa, USA)

P4

Preclinical testing of trail therapeutics for sarcoma  
Zakareya Gamie (Newcastle upon Tyne, UK)

P5

Humanized mouse models of triple-negative and triple-positive breast cancer bone metastasis for preclinical validation of novel immuno-oncology therapies  
Mari I Suominen (Turku, Finland)

P6

Preventing and repairing myeloma bone disease by combining conventional anti-resorptive treatment with a novel bone anabolic treatment  
Jenny Down (Sheffield, UK)

P7

Inhibiting IL-1B signalling increases therapeutic efficacy of doxorubicin and zoledronic acid in immunocompetent models of mammary cancer bone metastases.  
Penelope Ottewell (Sheffield, UK)

P8

Tumour derived IL-1B Induces differential tumour promoting mechanisms in breast cancer bone metastasis  
Penelope Ottewell (Sheffield, UK)

P9

Interleukin-34 as a potential therapeutic target for the treatment of osteosarcoma  
Kristina Schiavone (Sheffield, UK)

P10

Combination of capecitabine and radium-223 for patients with breast cancer and bone metastases: Results of the CARBON trial phase IB initial safety stage

Janet Brown (Sheffield, UK)

P11

Enrichment and detection of tumor cells in novel models of breast cancer bone colonization

Miranda Sowder (Nashville, USA)

P12

Panobinostat significantly prevents osteosarcoma progression and metastasis

Jeremy McGuire (Tampa, USA)

P13

BMP4 gene therapy inhibits myeloma tumor growth, but has a negative impact on bone

Marita Westhrin (Trondheim, Norway)

P14

Activation of osteoclast formation by hypoxia-inducible factor (HIF): a disease-specific mechanism in osteosarcoma?

Helen Knowles (Oxford, UK)

P15

Myeloid Derived Suppressor Cells promote Multiple Myeloma cell survival by AMPK activation

Kim De Veirman (Brussels, Belgium)

P16

The role of serum vitamin-D and bone turnover markers in prognosis of bone metastasis and prediction of benefit from adjuvant zoledronic acid in patients with early breast cancer.

Janet Brown (Sheffield, UK)

P17

Lysyl oxidase promotes survival and outgrowth of cancer cells in the bone marrow, enabling bone metastasis formation.

Caroline Reynaud (Lyon, France)

P18

Guidelines for the assessment and management of prostate cancer treatment-induced bone loss. A consensus position statement from a UK expert group.

Janet Brown (Sheffield, UK)

P19

Computational modeling of macrophage polarization dynamics in skeletal malignancies. An integrated in silico and in vivo approach

Chen Hao Lo (Tampa, USA)

P20

Abstract withdrawn

P21

Host-derived matrix metalloproteinase-13 contributes to the progression of multiple myeloma

Chen Hao Lo (Tampa, USA)

P22

Imaging upregulated cell surface proteins, altered tumor metabolism and structural bone changes in multiple myeloma

Monica Shokeen (St Louis, USA)

P23

The effects of cathepsin K inhibition on osteocytes: its role in bone restoration in MM bone disease

Masahiro Hiasa (Tokushima, USA)

P24

Human osteoclasts generated from different individuals show a highly variable sensitivity to zoledronic acid in vitro – this sensitivity relates to in vivo characteristics of each individual

Kent Søe (Vejle, Denmark)

P25

Investigating the osteoblast-breast cancer cell interaction at early stages of bone metastasis

Marie-Therese Haider (Hamburg, Germany)

P26

Defining the role of P2X7 receptor in the dormant population of prostate cancer cells

Hector Arredondo (Sheffield, UK)

P27

Characteristics of the stromal cells in the premetastatic and hematopoietic niches

Inaam Nakchbandi (Heidelberg, Germany)

P28

Learning from osteoblasts how to fight cancer

Inaam Nakchbandi (Heidelberg, Germany)

P29

Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth.

Georgia Stewart (Sheffield, UK)

P30

FACS-based isolation of primary and metastatic osteosarcoma cells in mice: a new tool to allow downstream molecular analysis and target identification  
Charlotte Palmer (Cambridge, UK)

P31

Osteoblast-Induced Cytonemes (OICs) facilitate breast cancer co-migration with osteogenic cells during breast cancer bone metastasis  
Aaron Muscarella (Houston, USA)

P32

Abstract withdrawn

P33

Inhibition of p62-ZZ Domain-Mediated Signaling in Myeloma Bone Disease Induces Osteoblast Differentiation and Overcomes Bortezomib Resistance.  
Silvia Marino (Indianapolis, USA)

P34

The Role of Receptor Activity Modifying Protein 1 in Prostate Cancer.  
Jessica Warrington (Sheffield, UK)

P35

Investigating the influence of bone marrow adipocytes on breast cancer metastasis  
Nadia Halidi (Oxford, UK)

P36

Leukaemia inhibitory factor: a novel mediator of prostate cancer bone metastasis?  
Christina Turner (Oxford, UK)

P37

Myeloma cell down-regulation of adiponectin in bone marrow adipose tissue promotes growth and survival via TNF-alpha  
Emma Morris (Oxford, UK)

P38

3D Perfusion Bioreactor Model of Tumor-Induced Bone Disease  
Joseph Vanderburgh (Nashville, USA)

P39

Unravelling the metabolic relationship in the prostate cancer-bone microenvironment; a novel role for the pentose phosphate pathway  
Jessica Whitburn (Oxford, UK)

P40

Effect of tumour-derived extracellular vesicles on the molecular profile of osteoblasts and on endothelial functions  
Riccardo Paone (L'Aquila, Italy)

P41

Osteolytic bone metastases in non-small cell lung cancer patients: the role of LIGHT  
Ilaria Roato (Bari, Italy)

P42

LKB1 deficiency exhibits vulnerable mitochondrial defects by rapamycin on urothelial carcinoma cells  
Young Mi Whang (Seoul, Republic of Korea)

P43

Pretreatment with metformin alters the host microenvironment to increase myeloma tumour burden and bone disease in vivo  
Beatriz Gamez (Oxford, UK)

P44

Marrow Adipose Tissue is Associated with Regions of Hypoxia During Metastatic Colonization of the Bone  
Colleen Wu (Durham, USA)

P45

Transcriptional regulators of oncogenesis and of osteoblastic differentiation revealed by microRNA profiling of osteosarcoma cell lines and primary human osteoblasts  
Brendan Norman (Liverpool, UK)

P46

Vascular cell adhesion molecule (VCAM) 1 and  $\alpha 4\beta 1$  integrin interactions regulate myeloid-derived suppressor cells (MDSC) mobilization from the bone marrow of tumor hosts  
Serk In Park (Seoul, Republic of Korea)

P47

Modelling the human bone-tumour niche ex vivo  
Srinivasa Rao (Oxford, UK)

P48

Contribution of marrow adipocytes to destructively lytic behavior of metastatic kidney tumors in bone  
Mackenzie Herroon (Detroit, USA)

P49

Combined administration of a novel small-molecule inhibitor of TRAF6 and Docetaxel reduces breast cancer skeletal metastasis and osteolysis  
Ryan Bishop (Sheffield, UK)

P50

Altering glycosphingolipid composition to improve multiple myeloma bone disease  
Houfu Leng (Oxford, UK)

P51

Transcriptomic profiling of the in vivo myeloma bone-lining niche identifies BMP signalling as a therapeutic target for bone disease

Sarah Gooding (Oxford, UK)

P52

Bone-specific activation of a dietary polyphenol inhibiting TGF $\beta$ -dependent breast cancer bone metastases

Janet L Funk (Tucson, USA)

P53

Development of Novel Nanomedicines for Treatment of Primary and Metastatic Prostate Cancer

Omer Aydin (Istanbul, Turkey)

P54

Mechanical signals retain musculoskeletal endpoints while suppressing adiposity in a murine model of complete estrogen deprivation

Gabriel M Pagnotti (Indianapolis, USA)

P55

Mechanical signals retain musculoskeletal endpoints while suppressing adiposity in a murine model of complete estrogen deprivation.

Gabriel M Pagnotti (Indianapolis, USA)

P56

Bone-sialoprotein (BSP), Dickkopf-1 (DKK1) and CXCR4 as potential biomarkers of breast cancer metastasis to bone: Analysis within the AZURE (BIG 01/04) study of adjuvant zoledronic acid.

Steven Wood (Sheffield, UK)

P57

Functionalized Rare earth-doped Nanoparticles for Breast Cancer Detection and Potential Bone-targeting Contrast Agents

Patricia Juárez (Ensenada, Mexico)

P58

An agent based model of the bone remodelling process and its disruption by multiple myeloma.

Curtis Palasiuk (Sheffield, UK)